Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Sulfadiazine

From Wikipedia, the free encyclopedia
Sulfa drug
Pharmaceutical compound
Sulfadiazine
Clinical data
AHFS/Drugs.comMonograph
MedlinePlusa682130
Routes of
administration
Topical cream, by mouth
Drug classAntibiotic (sulfonamide)[1]
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability?
Protein binding38-48%[1]
MetabolismLiver (acetylation)[1]
Eliminationhalf-life7-17 hours[1]
ExcretionUrine[1]
Identifiers
  • 4-amino-N-(pyrimidin-2-yl)benzenesulfonamide
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.000.623Edit this at Wikidata
Chemical and physical data
FormulaC10H10N4O2S
Molar mass250.28 g·mol−1
3D model (JSmol)
Melting point252 to 256 °C (486 to 493 °F)
  • Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
  • InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14) checkY
  • Key:SEEPANYCNGTZFQ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Sulfadiazine is anantibiotic.[1] Used together withpyrimethamine, adihydrofolate reductase inhibitor, it is the treatment of choice fortoxoplasmosis, which is caused by a protozoan parasite.[3] It is a second-line treatment forotitis media, prophylaxis ofrheumatic fever,chancroid,chlamydia, and infections byHaemophilus influenzae.[1] It is also used as adjunct therapy for chloroquine-resistant malaria and several forms of bacterial meningitis.[4] It is taken by mouth.[1] Sulfadiazine is available in multiple generic tablets of 500 mg. For urinary tract infections, the usual dose is 4 to 6 grams daily in 3 to 6 divided doses.[4]

Common side effects include nausea, diarrhea, headache, fever, rash, depression, andpancreatitis.[1] It should not be used in people who have severe liver problems, kidney problems, orporphyria.[3] If used duringpregnancy, it may increase the risk ofkernicterus in the baby.[1] While the company that makes it does not recommend use duringbreastfeeding, use is believed to be safe if the baby is otherwise healthy.[2] It is in thesulfonamide class of medications.[1]

Sulfadiazine was approved for medical use in the United States in 1941.[1][5] It is on theWorld Health Organization's List of Essential Medicines.[6] Sulfadiazine is available as ageneric medication.[1]

Medical uses

[edit]

It eliminatesbacteria that cause infections by stopping the production offolate inside the bacterial cell, and is commonly used to treaturinary tract infections and burns.

In combination, sulfadiazine and pyrimethamine can be used to treat toxoplasmosis, the disease caused byToxoplasma gondii.

Other uses

[edit]

Sulfadiazine is used inplant research forselecting and maintaining genetically manipulated cells.[7]

Mechanism of action

[edit]

Sulfadiazine works by inhibiting the enzymedihydropteroate synthetase.

Side effects

[edit]

Side effects reported for sulfadiazine includenausea,loss of appetite,dizziness, gastrointestinal upset, rash and fever.[4]

Brand names

[edit]

This drug is sold branded as Lantrisul, Neotrizine, Sulfadiazine, Sulfaloid, Sulfonamides Duplex and Sulfose.

"Triple sulfa" (ortrisulfapyrimidines) is a name often given to a combination of sulfadiazine withsulfamerazine andsulfamethazine. This is marketed under brand names such as Sulfa-Triple #2, Terfonyl, Triple Sulfa, Triple Sulfas and Triple Sulfoid.

See also

[edit]

References

[edit]
  1. ^abcdefghijklm"Sulfadiazine". The American Society of Health-System Pharmacists.Archived from the original on 20 December 2016. Retrieved8 December 2016.
  2. ^ab"Sulfadiazine Use During Pregnancy | Drugs.com".www.drugs.com.Archived from the original on 20 December 2016. Retrieved28 June 2017.
  3. ^abWorld Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.).WHO Model Formulary 2008. World Health Organization. pp. 126, 205.hdl:10665/44053.ISBN 9789241547659.
  4. ^abc"Sulfadiazine",LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012,PMID 31643992, retrieved2021-12-27
  5. ^"Drugs@FDA: FDA Approved Drug Products".www.accessdata.fda.gov. Archived fromthe original on January 17, 2020. Retrieved11 November 2018.
  6. ^World Health Organization (2019).World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization.hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  7. ^Kobercová E, Srba M, Fischer L (March 2023). "Sulfadiazine and phosphinothricin selection systems optimised for the transformation of tobacco BY-2 cells".Plant Cell Reports.42 (3). Springer Science and Business Media LLC:535–548.Bibcode:2023PCelR..42..535K.doi:10.1007/s00299-022-02975-7.PMID 36609768.S2CID 255501050.

External links

[edit]
Antifolates
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
DHFR inhibitor
Sulfonamides
(DHPS inhibitor)
Short-acting
Intermediate-acting
Long-acting
Other/ungrouped
Combinations
Other DHPS inhibitors
Quinolones
(inhibit bacterial
topoisomerase
and/orDNA gyrase,
thereby inhibiting
DNA replication)
1st generation
Fluoroquinolones
2nd generation
3rd generation
4th generation
Veterinary
Newer non-fluorinated
Related (DG)
Anaerobic DNA
inhibitors
Nitroimidazole derivatives
RNA synthesis
Rifamycins/
RNA polymerase
Lipiarmycins
Alveo-
late
Apicom-
plexa
Conoidasida/
(Coccidiostats)
Cryptosporidiosis
Isosporiasis
Toxoplasmosis
Aconoidasida
Malaria
Individual
agents
Hemozoin
inhibitors
Aminoquinolines
4-Methanolquinolines
Other
Antifolates
DHFR inhibitors
Sulfonamides
Co-formulation
Sesquiterpene
lactones
Other
Combi-
nations
Fixed-dose (co-formulated)ACTs
Other combinations
(not co-formulated)
  • artesunate/mefloquine
  • artesunate/SP
  • quinine/clindamycin
  • quinine/doxycycline
  • quinine/tetracycline
Babesiosis
Cilio-
phora
Stramen-
opile
Portal:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sulfadiazine&oldid=1307197285"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp